🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the effort against superbug strains of the infection, according to health experts.

An International Public Health Issue

Cases of gonorrhoea are on the rise globally, with data suggesting over 82 million instances each year. Particularly high rates are observed in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Medical experts are increasingly worried about the rise in drug-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program found that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Gain Approval

One new antibiotic, marketed under the name a brand name, was authorized by the US FDA in mid-December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is also used to treat UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This milestone marks a major breakthrough in the treatment of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Results and Worldwide Availability

As per data published in a prominent scientific publication, the new drug eradicated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which involves an injection and a pill. The trial included over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to register and commercialise the drug in a wide range of developing nations.

Clinicians treating patients have voiced hope. Having a single-dose, oral treatment of this kind is described as a "critical tool" for gonorrhoea control. This is considered crucial to lessen the impact of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea globally.